Study of the Efficacy and Safety Of Apremilast (CC-10004), in Subjects With Moderate Plaque Psoriasis

Inclusion Criteria:

- Males or females, ≥ 18 years of age

- Able to adhere to the study visit schedule and other protocol requirements.

- Diagnosis of chronic plaque psoriasis for at least 6 months prior to signing the
informed consent.

- Have moderate plaque psoriasis at screening and baseline as defined by

- Must be in general good health (except for psoriasis) as judged by the investigator,
based

- No prior systemic treatments or biologics for the treatment of psoriatic arthritis,
psoriasis

- Females must have a negative pregnancy test at screening and baseline. Participants
must agree to use contraception during the course of the study

Exclusion Criteria:

- Other than psoriasis, any clinically significant (as determined by the Investigator)
major disease that is currently uncontrolled.

- Any condition, including the presence of laboratory abnormalities, which would place
the subject at unacceptable risk if he/she were to participate in the study.

- Pregnant or breast feeding.

- Active substance abuse or a history of substance abuse within 6 months prior to
signing the informed consent.

- Malignancy or history of malignancy

- Topical therapy within 2 weeks of starting trial

- Use of phototherapy within 4 weeks prior to starting trial

- Use of any investigational drug within 4 weeks prior to starting trial

- Prolonged sun exposure or use of tanning booths, which may confound the ability to
interpret data from the study.

- Prior treatment with apremilast.